Biocon share price today opened at ₹325.25 apiece on the BSE, the stock touched an intraday high of 328.90, and an intraday low of 321.15 per share.(Unsplash) Biocon share price rose by 2.5% ...

Biocon Limited announced on Friday that it has launched its Glucagon Glucagon-like Peptide-1 (GLP-1) analog, Liraglutide, in the United Kingdom (U.K.). The drug is recommended for treatment of ...

BRIDGEWATER, N.J., and BENGALURU, India, March 7, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code ...

BRIDGEWATER, N.J. and PETERSBURG, Va. and BENGALURU, India, March 6, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd ...

Biocon Biologics has commercialized eight biosimilars in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, and Japan.It has a pipeline of 12 biosimilar assets under ...

Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to ...

We are excited to be among the first companies to introduce a high-quality, affordable biosimilar Ustekinumab to this patient population,” Shreehas Tambe, CEO & Managing Director, Biocon ...

India's Biocon has expanded its pipeline of biosimilars with a $3.3 billion deal to acquire a portfolio of drugs from Viatris, the parent of its longstanding partner Mylan, which will boost its ...

Biocon Ltd share price was up by 1.50% from the previous closing price of ₹336.35. Who are peers of Biocon Ltd? The peers of Biocon Ltd are Sun Pharmaceuticals Industries Ltd, Divis Laboratories ...

Let's catch up on the latest news from the stock market. From significant investments to major deals, appointments, and acquisitions, here’s a quick look at which stocks will be in focus in ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...